HGG-52. SUSTAINED RESPONSE TO CRIZOTINIB MONOTHERAPY IN AN INFANT WITH GOPC-ROS1 FUSED CONGENITAL HEMISPHERIC GLIOMA

MLA

Douglas C. Anthony, et al. “Hgg-52. Sustained Response to Crizotinib Monotherapy in an Infant with Gopc-Ros1 Fused Congenital Hemispheric Glioma.” Neuro-Oncology, vol. 22, no. Suppl 3, Dec. 2020, p. iii353. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bf93aeca85723fa7f7d87573f5b32d87&authtype=sso&custid=ns315887.

APA

Douglas C. Anthony, Kristine Pelton, Keith L. Ligon, Rishi Lulla, Konstantina A. Svokos, & Mehdi Touat. (2020). Hgg-52. Sustained Response to Crizotinib Monotherapy in an Infant with Gopc-Ros1 Fused Congenital Hemispheric Glioma. Neuro-Oncology, 22(Suppl 3), iii353.

Chicago

Douglas C. Anthony, Kristine Pelton, Keith L. Ligon, Rishi Lulla, Konstantina A. Svokos, and Mehdi Touat. 2020. “Hgg-52. Sustained Response to Crizotinib Monotherapy in an Infant with Gopc-Ros1 Fused Congenital Hemispheric Glioma.” Neuro-Oncology 22 (Suppl 3): iii353. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bf93aeca85723fa7f7d87573f5b32d87&authtype=sso&custid=ns315887.